Has launched an enhanced edition of its proprietary LabStarSM system.

Appropriately, for all biological products, FDA intends to designate a non-proprietary name that includes a suffix composed of four lowercase letters.’ Related StoriesPreventing falls in treatment homes: an interview with Professor Pip LoganWHO focused on helping Nepal deliver healthcare to its residents, says WHO South-East Asia Regional DirectorNeurological examining accessibility and affordability: an interview with Dr Joseph HigginsAMCP CEO Edith A. Rosato, RPh, IOM, released the following declaration in response: The current naming convention using the same non-proprietary name has proven safe and effective globally for small molecule medicines and for biological products in Europe, and it must be the standard in the United States therefore.We think that ACT has never been better positioned to build up its promising stem cell-based technologies.A., GW's commercial partner in Germany, and the German National Association of Statutory MEDICAL HEALTH INSURANCE Funds . This fresh agreement has resulted in an increase to the previously reduced cost imposed by the German authorities in March 2013 which Almirall had regarded as unacceptable. It is estimated that approximately 4, 000 patients are currently being treated with Sativex in Germany. Almirall is focused on meeting the requirements of MS patients and this is the reason we have been determined over latest months to achieve an appropriate resolution of the reimbursement price in Germany, stated Farid Taha, General Manager of Almirall Hermal Firm.